secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273373
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna reports Q3 net income of $8.2M; cash at $561.6M into 2029; SEP-479 candidate selected
--------------------------------------------------------------------------------

- Q3 2025 net income $8.2M vs net loss $20.5M in Q3 2024; revenue $21.5M from Novo Nordisk collaboration.
- Cash and equivalents $561.6M, including $195M upfront from Novo Nordisk and $12.5M from Vertex; runway into 2029.
- Selected SEP-479 as oral PTH1R agonist development candidate for hypoparathyroidism; Phase 1 expected H1 2026.
- SEP-631 Phase 1 ongoing for mast cell diseases; initial data expected H1 2026.
- Appointed Keith Gottesdiener, M.D., to Board as chair of R&D Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/0001193125-25-273373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525273373/sepn-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer